Based on the earnings transcript, I anticipate a moderately positive short-term impact on J&J's stock price. Key positives include solid operational growth in pharmaceuticals (4.9%), particularly strong performance of new products like ZYTIGA, and management's confident tone about business momentum. While there are some headwinds like continued softness in medical device procedures and European austerity measures, these appear to be already factored into expectations. The company maintained/raised guidance and showed disciplined cost management despite increased investment spending.

[1]